LIFT is prospective randomised marker-based trial to assess the clinical utility and safety
of biomarker-guided immunosuppression withdrawal in liver transplantation. 'LIFT' aims to
validate a biomarker test of operational tolerance to stratify liver transplant recipients
before withdrawing immunosuppressive medication. Primary objective is clinical utility and
risk/benefit ratio of employing a transcriptional test of tolerance to stratify liver
recipients prior to immunosuppression withdrawal. Secondary objectives are: safety of
biomarker-guided immunosuppression withdrawal; health-economic and quality of life impact of
biomarker-guided immunosuppression withdrawal; improvement in drug-related co-morbidities;
prevalence of tolerance over time; role of donor-specific anti-human leukocyte antigen (HLA)
antibodies; identify mechanisms of liver allograft tolerance. It is a prospective,
multi-centre, phase IV, biomarker-strategy design trial with a randomized control group in
which adult liver transplant recipients will undergo immunosuppression withdrawal. The sample
size is 148 patients.
Phase:
Phase 4
Details
Lead Sponsor:
King's College London
Collaborators:
King's College Hospital NHS Trust National Institute for Health Research, United Kingdom